Neurological Disorder Drugs Market
Neurological Disorder Drugs Market (Disorder - Epilepsy, Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, and Cerebrovascular Disease; Drug Type - Anticholinergic, Antiepileptic, Antipsychotic, Analgesics, Hypnotic & Sedative, Antihypertensive, and Anticoagulants; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and eCommerce) - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
- 224 Pages
Europe Neurological Disorders Drugs Market: Snapshot
Several government initiatives across various countries to educate masses about the rise of various diseases and increasing healthcare sector producing new drugs are the prime reasons for growth of neurological disorder drugs market. European Parkinson’s Disease Association, in Europe is actively supporting research and development by campaigning to raise awareness, and providing medication to patients is boosting the overall neurological disorder drugs market. This region is also witnessing rising focus on research and development programs that will help in producing affordable and effective drugs. The countries are collectively spending on developing neurological disorder drugs thus, improving the revenue of the market during the forecast period.
Staggering increase in brain altering disorders such as Alzheimer’s, epilepsy, Parkinson’s, cerebrovascular, and sclerosis are promoting the pharmaceutical firms to tap into the significantly growing neurological disorder drugs market. This will potentially supplement the market growth in the coming years. Rise of several innovative drugs to manage these diseases will swell up the investments in the market. Increasing number of clinical trials are another reason boosting the market. Rise in geriatric population along with patients with strokes, migraines, and headaches leading to cerebrovascular diseases are likely to augment the growth of the market.
The treatment for neurological disorders can be expensive due to several additional expenses related to sedatives and hypotonic, antiepileptic and anticholinergic drugs. There has also been decline in development of drugs due to expensive cost of research and development. Maturation of product portfolio can also cause decline in innovation. Strict policies to prescribe sedatives act as the major restrain in the market.
However, increasing prevalence of neurological disorders have the potential to create growth opportunities for the Europe neurological disorders drugs market. Rise in awareness regarding the diseases along with government’s support will boost the growth of the Europe neurological disorders drugs market.
The Europe neurological disorder drugs market is anticipated to rise at a healthy CAGR of 6.4% during the forecast period of 2015 to 2024. The Europe market was worth US$18.3 bn during 2015 and is expected to attain a valuation of US$32.0 bn by the end of the forecast period.
Europe Neurological Disorders Drugs Market to Rise Owing to Increased Prevalence of Cerebrovascular Diseases
The European neurological disorder drugs market is segmented according to disorder into cerebrovascular diseases, multiple sclerosis, Alzheimer’s diseases, Parkinson’s diseases, and epilepsy. Among these, cerebrovascular diseases are dominating the market with a rising CAGR of 6.9% and is expected to rise by the end of 2024. This segment held the largest shares in the market during 2015. The drug class segment of Europe neurological disorder drugs market are Anticoagulants, Antihypertensive, Analgesics, Hypnotic and Sedative, Antipsychotic, antiepileptic, and anticholinergic. The major distribution channel segment of the neurological disorder drugs in Europe are retail pharmacy, Ecommerce, and hospital pharmacy.
Germany Providing Lucrative Growth to Market Due to Rise of Geriatrics Population
The Europe neurological disorder drugs market is geographically segmented into Poland, Switzerland, Netherlands, Russia, U.K., Spain, Italy, France, Germany, and other parts of Europe. Among these, Germany held significant shares in the market during 2015. Germany is expected to dominate the market during the forecast period. This was followed by France. The market is rising in these regions due to increasing neurological disorder and improved awareness regarding the disease by government initiatives and support groups. Rising number of geriatric population in Germany is one of the leading factor for the rise of neurological disorders drugs in this region. The other leading regions in neurological disorders drugs market are Spain, Switzerland, Italy, and the U.K. Switzerland is also anticipated to provide several opportunities for growth to the overall neurological disorders drugs market.
Some of the leading companies operating in the Europe neurological disorders drugs market are GlaxoSmithKline plc., Novartis AG, Teva Pharmaceutical Industries Ltd., Astra Zeneca, Bayer AG, Boehringer Ingelheim GmbH, and Merck & Co. These players are involving in expanding their outreach geographically to reserve their dominance in the market.
Rising Disease Burden to Accelerate R&D in Europe Neurological Disorder Drugs Market
Despite some of the exemplary strides neurosciences have made in the past ten years, the burden of neurological disorders has been growing worldwide. A number of translational research has been fueled by collaborative efforts by industry players in Europe neurological disorder drugs market. A case in point is rare forms of Alzheimer’s Disease. The regional market has witnessed growth on the back of growing body of research in central nervous system disorders through public private partnerships. Europe is seeing growing participation of pharmaceutical companies, academicians, and government agencies, who are focusing on reducing the prevalence of neurological disorders. The advent of new biomarkers and growing number of trials by various stakeholders are enriching the drug pipeline for the regional market. Conditional approval pathways are one of the key measures that might spur drug development pipeline in the Europe neurological disorder drugs market. In recent years, industry players have come to recognize the importance of multipronged approaches in treating neurological disorders. Europe is expected to accelerate research by adopting regulatory frameworks that can aid in the execution of clinical trials. In recent years, the market has also benefited from the focus on increasing the reproducibility of results.
The rapidly emerging COVID-19 pandemic has severely impacts the economic activities and international trade since it struck the world in 2019. The new waves in 2021 in various developing and developed regions including in Europe in the wake of emerging new virus variants have raised fresh alarms for policy makers. This has triggered regional and national governments to consolidate their public health infrastructure. Healthcare providers are also relying on cutting-edge technologies to meet the needs of patients of neurological disorders on one hand while constantly focusing on reducing operational costs. In these testing times, where cost-cutting has become more crucial than ever to retain the receding bottom line, repurposing of drugs has attracted considerable interest among pharmaceutical companies. The complex endpoints of clinical trials have stimulated the adoption of this approach in expediting drug development to meet the vast unmet need in the Europe neurological disorder drugs market.
Europe Neurological Disorder Drugs Market: Overview
This report on the neurological disorder drugs market studies the current as well as future prospects of the market in Europe. Health concern related to life threatening diseases are the major concerns in the developed and developing countries of Europe.
This research report provides a detailed analysis of the neurological disorder drugs market and helps understand the various driving factors for the growth of the market. The market overview section analyzes market dynamics and trends such as drivers, restraints and opportunities that influence the current nature and future status of the market. Market dynamics factors such as market attractiveness analysis have also been explained in order to deliver a thorough analysis of the overall competitive scenario of the Europe neurological disorder drugs market.
Europe Neurological Disorder Drugs Market: Segmentation
The neurological disorder drugs market has been segmented by disorder, by drug class, by distribution channel and by countries. The disorder segment has been sub-segmented into Epilepsy, Parkinson’s disease, Alzheimer’s disease, Multiple Sclerosis, Cerebrovascular disease and others. The drug class has been segmented into Anticholinergic, Antiepileptic, Antipsychotic, Analgesics, Hypnotic & Sedative, Antihypertensive, Anticoagulants and others. The distribution channel segment has been sub-segments into retail pharmacy, hospital pharmacy and eCommerce.
Europe Neurological Disorder Drugs Market: Scope
The executive summary provides detailed insights about the report and the market in general. This elaborate executive summary provides a glimpse into the present scenario of the Europe neurological disorder drugs market, which includes a market snapshot that provides overall information of various segments and sub-segments. The executive summary also provides overall information and data analysis of the Europe neurological disorder drugs market with respect to market segments based on disorder, drug class, distribution channel as well as geographic regions.
The market for neurological disorder drugs has been extensively analyzed based on their usefulness, effectiveness, sales revenue and geographic presence. The market size and forecast in terms of US$ Mn for each disorder, drug class, distribution channel as well as geographic regions has been provided for the period from 2016 to 2024. This report on the neurological disorder drugs market also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2016 to 2024, considering 2015 as the base year.
Europe Neurological Disorder Drugs Market: Regional Outlook
Geographically, the neurological disorder drugs market has been segmented into 10 major regions: Germany, France, Italy, Spain, U.K., Russia, Switzerland, Netherlands, Poland and Rest of Europe. The market size and forecast for each of these regions have been provided for the period from 2016 to 2024, along with CAGR (%) for the forecast period from 2016 to 2024. The research study also incorporates the competitive scenario in these regions.
Key Players Mentioned in this Report are:
A list of recommendations has been provided for new entrants as well as existing players to help establish a strong presence in the market and increase market share. The report also profiles major players in the neurological disorder drugs market based on various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Major players profiled in this report include Merck & Co., Boehringer Ingelheim GmbH, Bayer AG, Astra Zeneca, F-Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Novartis AG, and GlaxoSmithKline plc.
The Europe Neurological Disorder Drugs market is segmented as follows:
- Europe Neurological Disorder Drugs Market Revenue, by Disorder
- Alzheimer’s disease
- Parkinson’s disease
- Multiple Sclerosis
- Cerebrovascular disease
- Europe Neurological Disorder Drugs Market Revenue, by Drug Class
- Hypnotic & Sedative
- Europe Neurological Disorder Drugs Market Revenue, by Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Europe Neurological Disorder Drugs Market Revenue, by Geography
- Rest of Europe